ERR2598319
fetal · fetal
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- fetal
- cancer_type_detailed
- —
- subtype
- fetal
- cancer_type
- fetal
- subtype
- fetal
- sex
- fetal
- race
- fetal
- fetal_age_hindbrain
- 20
- umap1_2d
- -4.960102728
- umap2_2d
- 0.157958641
- umap1_3d
- 0.033337408
- umap2_3d
- 1.894958888
- umap3_3d
- 0.413637857
- dataset
- fetal
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- IL6_JAK_STAT3_SIGNALING+0.620
- INTERFERON_ALPHA_RESPONSE+0.600
- INFLAMMATORY_RESPONSE+0.590
- INTERFERON_GAMMA_RESPONSE+0.590
- COAGULATION+0.520
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.520
- ALLOGRAFT_REJECTION+0.510
- ANGIOGENESIS+0.500
- TNFA_SIGNALING_VIA_NFKB+0.490
- COMPLEMENT+0.480
Top 10 suppressed
- MYC_TARGETS_V1-0.670
- MYC_TARGETS_V2-0.650
- E2F_TARGETS-0.620
- G2M_CHECKPOINT-0.600
- DNA_REPAIR-0.450
- MITOTIC_SPINDLE-0.440
- UNFOLDED_PROTEIN_RESPONSE-0.390
- PI3K_AKT_MTOR_SIGNALING-0.250
- MTORC1_SIGNALING-0.240
- OXIDATIVE_PHOSPHORYLATION-0.230
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
3 twins match this tumor's tissue · 7 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MDT-AP-1254 | Med | Medulloblastoma | 0.956 |
| 2 | SRR1444622 | GTEX | — | 0.948 |
| 3 | SRR5088905 | — | — | 0.942 |
| 4 | ERR2598312 | fetal | fetal | 0.940 |
| 5 | SRR1079591 | GTEX | — | 0.938 |
| 6 | SRR1352954 | GTEX | — | 0.936 |
| 7 | BS_3XY76V8T | Ganglioglioma | — | 0.936 |
| 8 | BS_KXH37MPN | DNET | — | 0.930 |
| 9 | SRR1431345 | GTEX | — | 0.930 |
| 10 | sclc0617_S65.txt | — | cohortMD2 | 0.930 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 34 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| IL6_JAK_STAT3_SIGNALING | 0.620 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.600 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.590 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.590 | Idelalisib | — uncovered |
| COAGULATION | 0.520 | Binimetinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.520 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.510 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.500 | Remibrutinib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.490 | Inavolisib | — uncovered |
| COMPLEMENT | 0.480 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.420 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.420 | Inavolisib | — uncovered |
| MYOGENESIS | 0.410 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.390 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.390 | Inavolisib | — uncovered |
| APOPTOSIS | 0.350 | Idelalisib | — uncovered |
| HYPOXIA | 0.330 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.320 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.320 | Cobimetinib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.310 | Inavolisib | — uncovered |